The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose)
First participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
Learn MoreSean M. Healey & AMG Center for ALS
News & Events
Massachusetts General Hospital reports on news from the Sean M. Healey & AMG Center for ALS at Mass General on clinical trials, progress in research, and recognition for clinical excellence.
News
Recent Media Coverage
View All
The AthleticMay | 10 | 2022
Tim Green Fought ALS Diagnosis Until it Nearly Killed Him, and Now He’s Fighting Back
The Athletic features a moving profile of NFL star, writer and ALS activist Tim Green and his family.
Morris ALS PrinciplesApril | 25 | 2022
HEALEY ALS Platform Trial Wins Morris ALS Principles Award
The Morris ALS Principles award honored the HEALEY ALS Platform Trial team for their work to include people with ALS in planning and development of the trial and for using Expanded Access Protocols to give more people access to potential therapies.
Make a Difference for the Healey Center
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.